Treatment progress of severe aplastic anemia / 器官移植
Organ Transplantation
; (6): 293-2020.
Article
in Zh
| WPRIM
| ID: wpr-817608
Responsible library:
WPRO
ABSTRACT
Severe aplastic anemia (SAA) is a rare type of bone marrow hematopoietic failure, which is associated with toxic T lymphocyte-based immune dysfunction, abnormal hematopoietic microenvironment and damage of hematopoietic stem cells in patients. SAA characterized by acute onset, rapid progression and high mortality rate, which requires rapid and stable recovery of the patients' hematopoietic function. In this article, the therapeutic progresses on immunosuppressive therapy (IST), sibling human leukocyte antigen (HLA)-matched allogenetic hematopoietic stem cell transplantation (allo-HSCT), replacement of donor hematopoietic stem cell transplantation and unrelated umbilical cord blood hematopoietic stem cell transplantation (UCBT) for SAA were reviewed.
Severe aplastic anemia; Human leukocyte antigen; Immunosuppressive therapy; Haploidentical hematopoietic stem cell transplantation; Overall survival; Antithymocyte globulin; Allogeneic hematopoietic stem cell transplantation; Umbilical cord blood hematopoietic stem cell transplantation; Graft-versus-host disease
Full text:
1
Database:
WPRIM
Language:
Zh
Journal:
Organ Transplantation
Year:
2020
Document type:
Article